Pfizer Inc.’s oral rheumatoid arthritis drug Xeljanz reduced death or respiratory failure in hospitalized Covid-19 patients with pneumonia in Brazil, meeting the study’s main goal.

A sense of urgency, powerful science, relentless ingenuity, hope and trust drove the development of Pfizer and BioNTech’s mRNA vaccine during the height of the Covid-19 pandemic. As the crisis appears to lessen, Pfizer is preparing for the next pandemic.

The United States on June 10 raised the pressure on other Group of Seven (G7) leaders to share their vaccine hoards to bring an end to the pandemic by pledging to donate 500 million doses of the Pfizer coronavirus vaccine to the world’s poorest countries.

Preliminary findings from two vaccine safety monitoring systems suggest a higher-than-expected number of cases of heart inflammation after the second dose of mRNA Covid-19 vaccines in young men, the U.S. Centers for Disease Control and Prevention (CDC) said on June 10.

The Biden administration plans to donate 500 million Pfizer coronavirus vaccine doses to nearly 100 countries over the next two years, three sources familiar with the matter told Reuters on June 9.

The U.S. Food and Drug Administration approved Pfizer Inc.’s Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older.

Pfizer Inc. will start a large study to test the company’s Covid-19 vaccine in children below 12 years and selected a dosing regime for the clinical trial.

Israel’s Health Ministry found the small number of heart inflammation cases observed mainly in young men who received Pfizer’s Covid-19 vaccine in Israel were likely linked to the company’s vaccination.

Europe’s medicines regulator on May 28 backed the use of Pfizer’s Covid-19 vaccine for children as young as 12, paving way for a broader roll-out in the region after similar clearances in the United States and Canada.

The U.S. Food and Drug Administration granted approval to Myfembree, Myovant Sciences and Pfizer’s once-daily treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Patients receiving the therapy under the newly approved indication can take the medicine for up to 24 months.